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[57] ABSTRACT 
The invention provides a new composition and method 
for the treatment of sickle cell anemia. The composition 
includes as an active ingredient an effective amount of 
the compound, phlorizin benzylazide: 
HO 
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H 
and an appropriate pharmaceutical excipient. Load and 
maintenance dosage ranges as well as effective blood 
concentration levels for the active ingredient are dis 
closed. 
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COMPOSITIONS AND METHOD OF TREATMENT 
FOR SICKLE CELL ANEMIA 
TECHNICAL FIELD 
This invention relates to the compound phlorizin 
benzylazide, pharmaceutical compositions thereof and 
their method of use for the treatment of sickle cell ane 
mia. 
BACKGROUND ART 
Sickle cell anemia results from a defect in the genetic 
coding of the hemoglobin molecule. The abnormal he 
moglobin S molecule in the red blood cells of sickle cell 
anemia patients is relatively insoluble and prone to 
deoxygenation-induced polymerization. When the 
sickle hemoglobin releases its oxygen at peripheral tis 
sue sites, it undergoes aggregation which distorts the 
red cell’s normal biconcave disc appearance and the 
characteristic spiculated, “holly leaf’ or sickle shape is 
formed. This aberrant cell distortion accounts for the 
clinical problems in this disease, namely hemolytic ane 
mia and vascular stasis, occlusion and thrombosis. 
The viscosity of the red blood cell interior is largely 
a function of hemoglobin concentration. When cell 
water content falls, the deformability of the red blood 
cell decreases. This compromises the ability of the red 
blood cell to maneuver through the microvasculature of 
the body. This effect is magni?ed in the deoxygenated 
sickle red blood cell because the rate at which the he 
moglobin S polymerizes is greatly accelerated by cellu 
lar dehydration, because aggregation is extremely de 
pendent upon the deoxy-hemoglobin S concentration. 
There is also evidence that the sickle cell becomes de 
hydrated during deoxygenation and this initiates the 
cell sickling. 
Additional research has indicated that a dysfunc 
tional membrane of the sickle red blood cell plays a 
fundamental roll in disease pathophysiology. Studies 
indicate that the deformation or sickling process result 
ing from deoxygenation requires about l0—l5 seconds 
to complete. Thus, it may be necessary for the blood in 
the microvasculature to slow abnormally before sick 
ling of most cells occurs. This slowing could be induced 
because of abnormal interactions between the sickle cell 
and the micro-blood vessel wall clue to an altered red 
blood cell membrane construction. There may also exist 
subpopulations of abnormally dense and in?exible red 
blood cells re?ecting cellular dehydration and in 
creased internal viscosity. 
These features are presumed to be due to altered ion 
flux and homeostasis controlled by the cell membrane. 
Furthermore, when a cell sickles and unsickles repeat 
edly, the membrane is affected and the cell becomes 
irreversibly sickled, remaining deformed even when the 
hemoglobin S is reoxygenated in the lungs. These irre 
versibly sickled cells (hereinafter ISC) have a drasti 
cally reduced water content and, thus, high hemoglobin 
concentrations, as well as high calcium and low potas 
sium content. They may also be ATP-depleted. ISC’s 
have short intravascular life-spans and the severity of 
the hemolytic process is directly related to the number 
of these cells in a patient’s circulation. Presumably, the 
permanently deformed cytoskeletons of the ISC’s make 
them unable to negotiate through capillaries. 
Based on the above evidence, researchers have 
sought a drug that would interact with the red blood 
cell membrane and increase sodium permeability and 
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2 
/or inhibit calcium uptake and potassium chloride plus 
water loss. Further, by preventing cellular dehydration, 
the drug would serve to preserve the deformability of 
the sickle red blood cell, prevent sickling, and be an 
extremely valuable therapeutic approach to the control 
of sickle cell anemia crisis. 
As a result, a large variety of structurally and mecha 
nistically dissimilar antisickling agents have been pro~ 
posed for the treatment of sickle cell anemia. So far, 
however, none of these have been found to be clinically 
useful. Most inhibit red blood cell sickling either by 
chemically modifying the hemoglobin S molecule to 
prevent its aggregation or by increasing red blood cell 
af?nity for oxygen. Approaches include the use of 
acetylators, such as aspirin; cross-linking agents, such as 
dimethyladipimidate; inhibitors of intra-molecular hy 
drophobic bonds, such as urea; and chemical group 
reactants, such as cyanate (as in U.S. Pat. No. 3,833,724 
to Cerami et al). 
Because of the critical role of hemoglobin S concen 
tration in the sickling process, it has been proposed that 
even a modest reduction of mean cell hemoglobin con 
centration in the sickle cell will greatly decrease any 
propensity to sickle. Clinical trials in which sickle pa 
tients on a low sodium diet were given anti-diuretic 
hormone to reduce plasma Na+~osmolality in hopes of 
producing a secondary reduction in cell hemoglobin S 
concentration had very limited success. Low plasma 
Na+ levels simply could not be maintained. Further, 
this is an ineffective means of increasing red blood cell 
water content. Other investigators have used the antibi 
otic Monensin to induce a Na+-selective leak in the red 
blood cell membrane. It was found that this Na+-iono 
phore produced an influx of sodium salt and water into 
the sickle cell. This increased hydration produced some 
improvemement in the deformability of the red blood 
cell. Disadvantageously, however, Monensin is highly 
toxic in experimental animals at micromolar levels. 
From the above, it is clear that a need exists for a safe, 
effective and clinically useful compound for the treat 
ment of sickle cell anemia. During the course of experi 
ments designed to photoaf?nity label and identify the 
glucose transport carrier in normal human red blood 
cells, we- found that phlorizin benzylazide caused he 
molysis of the red blood cells under certain conditions. 
The phlorizin derivative has a high, but reversible, af 
?nity for the sugar transporter in subdued light and is a 
potent inhibitor of the transfer mechanism. After allow 
ing the compound to associate with its speci?c mem 
brane receptor, activation with light was expected to 
result in relatively speci?c, covalent, irreversible label 
ing of the transporter. However, in our initial experi 
ments, even before illumination, the red blood cells 
were found to swell and, in a time and drug dose 
dependent manner, burst even in an isotonic buffer. 
These results suggested to us that this compound has 
potential usefulness as a membrane perturbant and anti 
sickling agent. Further experiments were then con 
ducted to demonstrate the safety and effectiveness of 
phlorizin benzylazide for use in a method of treating 
sickle cell anemia. 
SUMMARY OF THE INVENTION 
It is, accordingly, one object of the present invention 
to provide pharmaceutical compositions, including 
phlorizin benzylazide as an active ingredient, for the 
effective and safe treatment of sickle cell anemia. 
4,665,058 
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A further object of the present invention is to provide 
a safe and effective method of use of phlorizin benzyla 
zide containing compositions in treating sickle cell ane 
mla. 
Other objects and advantages of the present invention 
will become apparent as the description thereof pro 
ceeds. 
In satisfaction of the foregoing objects and advan 
tages, there is provided by this invention anti-sickling 
compositions comprising as the active ingredient an 
effective amount of the compound phlorizin benzyla 
zide. Also provided are methods for administration of 
the anti-sickling compositions of this invention to pa 
tients suffering from sickle cell anemia and from the 
crisis episode of the disease. Preferably, the anti-sickling 
composition is administered in an intravenous load dos 
age of between 0.5-l.0 milligrams of the phlorizin ben 
zylazide active ingredient per kilogram of the patient. 
Since the active ingredient has an unusually long 
biological half-life of approximately 75 hours, mainte 
nance dosages of from 0.05 to 0.2 milligrams of phlori 
zin benzylazide per kilogram of patient weight are then 
administered to the patient daily. This procedure advan 
tageously serves to maintain an approximately 6—l2.5 
jtM concentration of phlorizin benzylazide (unbound) 
in the bloodstream of the patient. Phlorizin benzylazide 
at these concentration levels interacts with the red 
blood cell membrane, allowing salt and water to enter 
the cell under the osmotic drive of the impermeant 
hemoglobin. The additional salt and water swell the red 
blood cells to a spheroid shape and reduce the concen 
tration of hemoglobin S below a critical concentration 
so that upon deoxygenation, sickling does not occur. 
Additionally, doses of phlorizin benzylazide effective to 
prevent sickling at this concentration cause few or no 
sickle cells to burst. Further, at potentially therapeutic 
doses, phlorizin benzylazide is not grossly toxic and, 
therefore, provides a relatively safe method for treating 
sickle cell anemia. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 graphically demonstrates the kinetics of 
phlorizin benzylazide-induced hemolysis. 
FIG. 2 graphically shows that phlorizin benzylazide 
causes an increase in intracellular volume of red blood 
cells. 
FIG. 3 shows that red blood cell swelling and lysis 
are dependent upon the concentration of phlorizin ben 
zylazide present. _ 
FIG. 4 demonstrates how phlorizin benzylazide in 
hibits red blood cell sickling induced by deoxygenation. 
FIG. 5 graphically depicts the absorption and elimi 
nation rate of phlorizin benzylazide in rats. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As indicated above, the present invention is drawn to 
novel pharmaceutical compositions containing an effec 
tive amount of phlorizin benzylazide as the active ingre 
dient. The compositions are useful in the method of the 
present invention for treating sickle cell anemia. 
It is believed the structural features of phlorizin ben 
zylazide allow it to interact with a component of the red 
blood cell membrane, possibly the glucose transporter. 
The phlorizin benzylazide distorts the glucose trans 
porter or some other integral protein to form a micro 
pore or seam between the membrane proteins ‘and the 
lipid-bilayer of the membrane. Hemoglobin remains 
20 
30 
45 
55 
60 
4 
impermeant to this scam and, therefore, provides an 
osmotic force for water as well as salt to enter the red 
blood cell. This ?ux of water and salt serves to swell the 
red blood cell to a spheroid shape and reduce the con 
centration of hemoglobin S in the cell below a critical 
concentration, thereby preventing sickling or signifi 
cantly delaying sickling until the hemoglobin S can 
again become oxygenated. 
The pharmaceutical preparations or compositions of 
the present invention include an effective amount of the 
active ingredient phlorizin benzlyazide admixed with a 
pharmaceutical organic or inorganic excipient. Suitable 
excipients are substances that do not react with the 
novel inhibitory compounds. Speci?c examples of such 
excipients include water, peanut oil, olive oil or syrup. 
Of course, other known medicinal excipients may be 
used. 
Preferably, the compositions are designed and 
adapted to be administered parenterally such as by sub 
cutaneous depo injection or I.V. drip. Advantageously, 
this avoids the risks involved in oral administration 
wherein the phlorizin portion of the molecule could be 
hydrolyzed by the intestinal epithelia to phloretin. As is 
well known, phloretin readily enters the blood stream 
and causes at appropriate levels toxic effects at all sites 
in the body. 
As more fully shown in the examples discussed be 
low, an effective amount of the active ingredient is 
approximately a 6 to 12.5 uM blood level concentration 
of phlorizin benzylazide. At this concentration level 
there is little or no cell lysis due to the incoming ?ux of 
water and salt across the cell membrane. It, however, 
should be recognized that higher concentration levels 
of phlorizin benzylazide could be used, for example, in 
an emergency to combat a sickle cell crisis. The higher 
concentrations are anticipated to be followed by a trans 
fusion of whole blood to replace those red blood cells in 
the patient that burst under the in?uence of the phlori 
zin benzylazide and to bring the phlorizin benzylazide 
concentration level in the blood back down to a safer 
concentration range. 
Thus, it should be appreciated that the method of 
treating sickle cell anemia includes the step of adminis 
tering parenterally a load dosage of from 0.5-1.0 milli 
grams of phlorizin benzylazide per kilogram of patient 
weight. This, of course, may be done over a period of 
time intravenously or by one or more subcutaneous 
depo injections. 
The higher end of the range is appropriate when 
seeking to combat the effects of sickle cell crisis with 
dosage levels above the range providing increased risk 
of side effects from red blood cell lysis. The lower end 
and middle portion of the load dosage range is appropri 
ate when using phlorizin benzylazide as a prophylaxis 
with load dosages less than the range failing to provide 
satisfactory therapeutic or anti-sickling action. For ex 
ample, a load dosage level of approximately 0.75 mg per 
kilogram of patient weight provides the patient with a 
blood concentration level of phlorizin benzylazide ther 
apeutically effective in resisting hemolytic anemia and 
vascular stasis, occlusion and thrombosis associated 
with sickle cell anemia. Further, such load dosages 
bring the blood level concentration of phlorizin ben 
zylazide in the patient to approximately the 6—l2.5 uM 
level, on the .basis that the agent distributes solely in the 
extracellular fluid and is not sequestered in various 
body compartments. Advantageously, at this level, cell 
4,665,058 
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swelling and anti-sickling action are maximized with 
little or no red blood cell lysis occuring. 
An additional advantage of the composition of the 
present invention is the unusually long biological half 
life enjoyed by the phlorizin benzylazide. The half-life 
has been shown experimentally to be of approximately 
75 hours. Thus, after the load dosage is administered, 
initial anti-sickling action is long lived and maintenance 
dosage to maintain the blood cell concentration level at 
approximately the 6—12.5 uM level is quite small. In 
particular, 0.05 to 0.2 milligrams of phlorizin benzyla 
zide per kilogram of patient weight are required per day 
to continue to provide effective anti-sickling action to 
the patient. Again, it should be recognized that the 
higher end of the range is for combatting the effects of 
sickle cell crisis and the lower end and middle portion is 
for less severe periods of the affliction. For example, 
normally a maintenance dosage of approximately 0.125 
mg of phlorizin benzylazide per kilogram of patient 
weight provides effective therapeutic action. 
The following synthesis and examples are presented 
to further illustrate the invention, but it is not to be 
considered as limited thereto. In the examples, the for 
mation of synthetic intermediates was monitored by 
thin layer chromatography performed on Silica Gel 60 
F-254 plates using the solvent systems indicated. The 
structure of the isolated compounds was established 
spectrophotometrically. Proton-NMR spectra (100 
MHz) were recorded on a Varian HA-100 Spectrome 
ter using (CH3)4Si (=0.00) as internal standard and 
acetone-d6, acetic acid or trichlorosilene as solvents. 
Chemical shifts are given in ppm. Infra-red spectra 
were taken in KBr pellets on a Beckman IR-8 spectrom 
eter and ultraviolet spectra on an Aminco DW-2a 
UV/VIS spectrophotometer. 
Elemental and functional group analyses were per 
formed by Galbraith Laboratories, Knoxville, TN and 
by the Laboratorium ?ir Organische Chemie, Eiden 
genossische Technische Hochschule-Zentrum, Ziirich, 
Switzerland. 
Melting points were taken on a Thomas Hoover cap 
illary melting point apparatus and are uncorrected. , 
Synthesis of Phlorizin Benzylazide 
Phlorizin (7 mmol) and p-nitrobenzaldehyde (5 
mmol) were dissolved in 84 ml methanol and cooled to 
0° C. Under a nitrogen atmosphere, 14 meq of 1N KOH 
were added dropwise with magnetic stirring and the 
reaction was allowed to incubate for 2 hrs. at 0° C. and 
then 1.5 hrs. at 50° C. The reaction mixture was re 
cooled to 0° C. and neutralized by the dropwise addi 
tion of 14 meq of 0.5N HCl. The solvent was removed 
in vacuo to yield a brown syrup containing primarily 
the presumed carbinol (carbinol was not sufficiently 
stable to be analyzed) and unreacted phlorizin. The 
mixture was dissolved in 10 ml CHCl3/CH3OH (4:1) 
and subjected to flash chromatography on a column of 
Silica Gel 60 (4.5><26 cm) that had been pressure 
packed with chloroform. Elution was conducted with 
0.75 L 15% methanol in chloroform, followed by 0.5 L 
18% and then 0.5 L 22% of the same solvent mixture. 
Thin layer chromatography was used to monitor the 
fractionation: the’ eluate volume between 0.4-0.5 L 
contained essentially pure 2'-O-(B-D-gluco-pyranosyl) 
5'-p-nitrobenzy1 carbinol (hereinafter called GNC) (0.8 
g', 20%) while the 0.5-1.4 L eluate contained 2.4 g of a 
mixture of GNC contaminated with approximately 20% 
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phlorizin. Rfvalue of the presumed compound GNC in 
25% MCOH/CHC13 was 0.25. 
Compound GNC (0.96 g in 100 ml methanol) was 
catalytically hydrogenated with 150 mg 10% Pd on 
charcoal for 1 hr at 22° C. at atmospheric pressure, and 
then 3 hr. at 55° C. at 30 cm H2O pressure. At lower 
temperatures reduction was incomplete and yielded an 
unstable orange product. The catalyst was removed and 
the methanol was evaporated in vacuo to yield crude 
phlorizin-5’-benzylamine (0.84 g, 92%). The product 
was dissolved in 8 ml methanol and mixed with 10 ml 
Sephadex G-10 slurry equilibrated in 50% methanol. ‘ 
Finally 8 ml H2O was added and the resulting slurry 
was added to the top of a Sephadex G-lO column (2.5 X 
27 cm) likewise equilibrated in 50% methanol. Elution 
was conducted with 0.8 L 50% methanol followed by 
0.7 L 55% methanol and 1.0 L 60% methanol. The 
amine was eluted in the 1.1-2.0 L fraction. If the amine 
had been contaminated prior to this chromatography, 
phlorizin was readily separated at this step and could be 
recovered in the 0.36-0.66 L fraction. Phlorizin-5'-ben 
zylamine was obtained by evaporating the solvent and 
crystallization from aqueous methanol as the monohy 
drate (0.55 g, 60%); after drying at 80° C. in vacuo its 
m.p. was l97°—200° C. 
Elemental Analysis: 
C H N 
Calculated for C28H31010N.H201 60.10 5.94 2.54 / 
Found for the reaction product: 60.30 5.90 2.51 
In order to verify that the reaction conditions were 
sufficient to reduce the secondary hydroxyl group of 
GNC, the phlorizin-5’-benzylamine reaction product 
was quantitatively acetylated with acetic anhydride in 
the presence of pyridine. Theoretical incorporation is 8 
moles acetate/mole glycoside. Found for phlorizin-5' 
benzylamine: 7.82 moles acetate/mole phlorizin-5’-ben 
zylamine (97.8%). 
An acetamide derivative of the reaction product pre 
pared by coupling acetic acid and the amine in methanol 
with EDAC, was crystallized from 30% methanol as 
the monohydrate. After drying at 80° C. in vacuo its 
m.p. was: 215° C. after softening at 149° C. 
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Elemental Analysis: .. 
H C N 
~ Calculated for C30H33O1 1N: 61.64 5.69 2.49 
Found for acetamide derivative 61.58 5.90 2.32 
of the reaction product: 
Further evidence con?rming the compound to be 
phlorizin-5'-benzylamine was provided by comparing 
its proton NMR spectra with that of phlorizin. The 
A2B2'pattern at 2.88 and 3.50 ppm arising from the 
—CH2CH2CO- moiety in phlorizin also appears at 
2.87 and 3.49 ppm in the spectra of phlorizin-5’-benzyla 
mine (in both compounds the triplet at 3.5 ppm is par 
tially obscured by the signals arising from the protons in 
the glucose moiety). The B-ring AA’BB'-system at 6.72 
and 7.10 ppm remained unchanged, but phlorizin’s A 
ring AB-system at 5.99 and 6.25 ppm was converted to 
a 1H singlet at 7.42 ppm in compound phlorizin-5’-ben 
zylamine. The new C ring AA'BB’ system in compound 
phlorizin-S-benzylamine gave signals at 6.54 and 6.98 
4,665,058 
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ppm and the new —CH2 group is seen as a 2H singlet at 
3.72 ppm. 
Since phlorizin benzylazide was expected to be 
photolabile, it was synthesized and isolated in subdued 
light. Cold 0.5N HCl (1.4 meq) was added slowly with 
magnetic stirring to 0.14 mmol of the phlorizin-5’-ben 
zylamine in 8 ml acetone (—2° C.) followed by drop 
wise addition of 0.28 mmol NaNOg in 0.5 ml H2O. The 
reaction mixture was stirred for 5 min and then l.4 
mmol NaN3 (in 1 ml H2O) was added. After 10 minutes 
excess urea was added with stirring. Acetone was then 
removed in vacuo and the product azide was precipi 
tated from the reaction mixture by slow addition of ice 
cold H2O. The isolated material was recrystallized from 
15 ml 30% aqueous methanol to yield small white crys 
tals as the monhydrate (0.053 g, 60%) with the follow 
ing m.p.: softens at 115° C., discolors 205° C., decom 
poses >250° C. R/=0.44 in chloroform/methanol, 7:3. 
The infra-red spectra possessed the sharp 2120 cm-1 
and 1280 cm~1 absorption peaks characteristic of an 
azide group. It has two major UV absorption maxima in 
ethanol or water; one at 255 nm attributable to the azide 
group, and the second at 280 nm which shifts to 334 nm 
in 0.05M sodium borate, pH 9.3 (334=2.95>< 104 cm-1 
M-l, 255=2.35>< 104 cm'-1M-1. 
EXAMPLE 1 
Human red blood cells were obtained by venepunc 
ture into Na citrate or EDTA vacutainers. They were 
used directly or stored in serum at 4° C. for various 
times. Serum and leucocytes were removed by siphon 
ing and the settled red blood cells were washed once 
and ?nally made to a 0.15% suspension with isotonic 
NaCl containing 5 mM KH2PO4 (pH 6.2). These cells 
were kept at 2° C. for selected periods of time during a 
?rst incubation. From this point on, all experiments 
were performed in subdued light to protect the light 
sensitive phlorizin benzylazide. The phlorizin benzyla 
zide obtained from the synthesis described above was 
added at the desired concentrations, and during this 
variable temperature second incubation (2°-4° C. in 
presence of phlorizin benzylazide), the turbidity of the 
cell suspension was monitored at 610 nm with a continu 
ously recording spectrophotometer to measure hemoly 
sis. A relatively constant level of absorbance of light 
indicates decreased hemolysis occurring at the lower 
dosage and this was veri?ed by concomitant counting 
of cells with a hemacytometer. Some typical data are 
shown in FIG. 1 showing the change in absorbance of 
light (note axis A) when the drug was added (at zero 
time). The higher level of Phlorizin Benzylazide caused 
not only a greater percentage of cell lysis (an absor 
bance of 0.087 represents 100% lysis) but the rate at 
which the cells burst was much faster. 
Evidence that lysis is preceded by a progressive 
swelling of the red cell is shown in FIG. 2. In these 
experiments (n=2) red cells had been stored in serum 
for 30 hours, and experienced a ?rst incubation for 60 
min at 4° C. and a second incubation with 12.5 )uM 
phlorizin benzylazide at 4° C. for 5 and 10 min. The 
integrated curves show that untreated red cells, with or 
without a 10 min incubation #2, have a mean volume of 
about 80 p3. When the compound is added, a time de 
pendent increase in mean cell volume occurs with es 
sentially no lysis within this time span (area under the 
curve remained unchanged). The Coulter Counter, an 
automated instrument which determines the number 
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and volume of cells passing through an analysis cham 
ber, was used to make these measurements. 
The dose-response curve of phlorizin benzylazide 
acting as a hemolytic agent of normal cells is shown in 
FIG. 3 and the following table: 
Phlorizin Benzylazide, K M % Hemolysis t; 
62 66 i 8 233 
Si 41 i 9.6 260 
16 31 i 8.6 450 
8 O — 
4 o _ 
In FIG. 3, potency is expressed as the ratio, % hemoly 
sis/t5, where t; represents the time (seconds) required to 
achieve 50% of the total hemolysis produced by the 
particular concentration of the compound within the 
time of our measurements (700 sec). The cells used for 
these experiments were 2 hours old, and subjected to an 
incubation for 30 minutes before the addition of phlori 
zin benzylazide and continuing thereafter at approxi 
mately 4° C. (n=4). Advantageously, cell swelling oc 
curred at low phlorizin benzylazide levels and no cell 
lysis was observed at concentrations below 10 uM. 
Thus, this blood level concentration provides anti-sick 
ling action by reducing the concentration of hemoglo 
bin S with an in?ux of water and/or salt into the cells. 
Further, this is accomplished with little or no red blood 
cell lysis and, therefore, minimum adverse side effects. 
EXAMPLE 2 
This example demonstrates that phlorizin benzylazide 
inhibits sickling induced by deoxygenation in vitro. 
Whole blood was obtained from several volunteer 
sickle cell disease patients and was stored for several 
days at 4° C. However, for these experiments, the cells 
did not experience a cold incubation. Instead, whole 
blood was diluted into pre-warmed (37° C.) isotonic 
phosphate-buffered saline (1 phlorizin benzylazide, 
12.5 uM) which was then deoxygenated by continuous 
passage of an 100% Argon stream (1 liter/min) over a 
rotating thin ?lm of the suspended cells. Aliquots were 
periodically taken, without 02 exposure, and ?xed in 
1% glutaraldehyde. These samples were then examined 
under phase microscopy for the degree of sickling by 
counting ?elds of at least 100 cells using a single blind, 
experimental protocol. 
The data shown in FIG. 4 illustrate that without 
phlorizin benzylazide present, about 35-40% of the 
cells from these patients assumed the typical sickle 
shape (only cells having a 3:1, lengthzwidth ratio were 
considered to be sickled); whereas, with the phlorizin 
benzylazide, the deoxygenation caused a maximum 
increase of 5% more than the 10% of cells already 
sickled at zero time. Actually, the effect of phlorizin 
benzylazide is even more dramatic. In the absence of 
phlorizin benzylazide, bizarre shape changes occurred 
in almost 100% of the cells when 02 tension was low 
ered; whereas, with the phlorizin benzylazide, a uni 
form spherocytosis was induced in most cells. The 
l0-l5% sickled cells present at zero time are probably 
the so-called irreversibly sickled cells (ISC). It should 
be emphasized that no signi?cant hemolysis occurred in 
Example 2. 
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EXAMPLE 3 
An animal study was then conducted to determine 
the absorption and elimination and characteristics of the 
phlorizin benzylazide and the resulting level of safety. 
Three adult rats of approximately 450 grams each were 
injected intraperitoneally at zero time in l, 2 and 3 mg 
doses of tritiated phlorizin benzylazide (875,000 
cpm/mg). Thereafter, serial tail blood samples were 
taken at varying times and analyzed for tritium. Maxi 
mal absorption of the-compound from the peritoneal 
compartment was slow (note FIG. 5) and maximum 
blood level concentrations were obtained only after 
about 20 hours. The initial very rapid entry and elimina 
tion of a small fraction of the radioactivity was probably 
tritiated H20 and other radioactive impurities. Peak 
concentrations of the agent in the blood were reached at 
identical times in the three animals and were 2.5, 5.1 and 
6.3 pM, roughly proportional to the dose administered. 
The absorption rate constant was estimated to be 0.07 
hr'-1. Elimination of the drug was a ?rst order process 
and the mean half life was an unusually long 75 hours as 
described above. This feature could, of course, offer 
advantages for therapy in a sickle cell crisis wherein 
long term effectiveness is desired. The animal receiving 
the lowest dosage was sacri?ced after 5 days while the 
other two were observed for a period of 7 weeks. None 
of the animals exhibited any unusual behavioral abnor 
malities. Gross examination of all tissues were un 
remarkable and histological examination of the liver 
and kidney from the two older animals showed no pa 
thology. 
In summary, numerous benefits have been described 
which result from employing the concepts of the pres 
ent invention. A novel pharmaceutical composition 
including an effective amount of the active ingredient 
phlorizin benzylazide is disclosed. The compositions are 
useful in a method for treating sickle cell anemia. Ad 
vantageously, the compositions serve to lower the he 
moglobin S concentrations in the red blood cells of 
sickle cell anemia victims and, thereby, prevent sick 
ling. As a further advantage, the biological half-life of 
the phlorizin benzylazide is approximately 75 hours. 
Therefore, the compositions provide a patient, particu 
larly when undergoing sickle cell anemia'crisis, with 
safe and effective long term anti-sickling action. Fur 
25 
40 
45 
ther, only minor maintenance dosages of the phlorizin ’ 
benzylazide are required to maintain the anti-sickling 
action over a still longer period. 
The invention has been described herein with refer 
ence to a certain preferred pharmaceutical composition 
embodiment. However, as obvious variations thereon 
55 
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will become apparent to those skilled in the art, the 
invention is not to be considered as limited thereto. 
We claim: 
1. A pharmaceutical composition for use in the treat 
ment of sickle cell anemia patients comprising as an 
active ingredient an effective amount of phlorizin ben 
zylazide. 
2. The composition set forth in claim 1, including a 
pharmaceutical excipient so as to be adapted for admin 
istration parenterally. 
3. The composition set forth in claim 1, in load dosage 
form including from 0.5-1.0 mg of active ingredient per 
kilogram of the patient. 
4. The composition set forth in claim 3, wherein said 
load dosageis approximately 0.75 mg of active ingredi 
ent per kilogram of the patient. 
5. The composition set forth in claim 1, in mainte 
nance dosage form including from 0.05 to 0.2 mg of 
active ingredient per kilogram of the patient per day. 
6. The composition set forth in claim 5, wherein said 
maintenance dosage is approximately 0.125 mg of active 
ingredient per kilogram of the patient per day. 
7. The composition set forth in claim 1, wherein said 
effective amount of said active ingredient is approxi 
mately a 6—12.5 PM concentration of phlorizin benzyla 
zide in the blood of the patient. 
8. A method for the treatment of sickle cell anemia in 
a patient comprising administering to the patient an 
effective dosage amount of phlorizin benzylazide. 
9. The method of claim 8 wherein said effective dos 
age amount of phlorizin benzylazide is administered 
parenterally in a pharmaceutical excipient as a composi 
tion. 
10. The method of claim 8, including the step of ad 
ministering a load dosage to the patient of from 0.5-1.0 
mg of phlorizin benzylazide per kilogram of the patient. 
11. The method of claim 10, wherein said load dosage 
is approximately 0.75 mg of phlorizin benzylazide per 
kilogram of the patient. 
12. The method of claim 8, including the step of ad 
ministering a maintenance dosage to the patient of from 
0.05 to 0.2 mg of phlorizin benzylazide per kilogram of 
the patient per day. 
13. The method of claim 12, wherein said mainte 
nance dosage is approximately 0.125 mg of phlorizin 
benzylazide per kilogram of the patient per day. 
14. The method of claim 8, including the step of main 
taining a phlorizin benzylazide concentration of approx 
imately 6—l2.5 uM in the blood of the patient to inhibit 
cell sickling. 
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